Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 198

1.

Long-term Edaravone Efficacy in ALS: Post-hoc Analyses of Study 19 (MCI186-19).

Shefner J, Heiman-Patterson T, Pioro EP, Wiedau-Pazos M, Apple S, Liu S, Zhang J, Agnese W.

Muscle Nerve. 2019 Oct 17. doi: 10.1002/mus.26740. [Epub ahead of print]

PMID:
31621933
2.

Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis.

Babu S, Macklin EA, Jackson KE, Simpson E, Mahoney K, Yu H, Walker J, Simmons Z, David WS, Barkhaus PE, Simionescu L, Dimachkie MM, Pestronk A, Salameh JS, Weiss MD, Brooks BR, Schoenfeld D, Shefner J, Aggarwal S, Cudkowicz ME, Atassi N.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Oct 14:1-9. doi: 10.1080/21678421.2019.1672750. [Epub ahead of print]

PMID:
31608711
3.

Clinical neurophysiology of anterior horn cell disorders.

Andrews JA, Shefner JM.

Handb Clin Neurol. 2019;161:317-326. doi: 10.1016/B978-0-444-64142-7.00057-6.

PMID:
31307610
4.

ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment.

Andrews JA, Bruijn LI, Shefner JM.

Neurology. 2019 Jul 9;93(2):66-71. doi: 10.1212/WNL.0000000000007695. Epub 2019 Jun 6. Review.

5.

A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.

Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA; VITALITY-ALS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2019;0(0):1-11. doi: 10.1080/21678421.2019.1612922. No abstract available. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2019 Jul 14;:1.

PMID:
31081694
6.

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.

Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC; ISIS-396443-CS2/ISIS-396443-CS12 Study Groups.

Neurology. 2019 May 21;92(21):e2492-e2506. doi: 10.1212/WNL.0000000000007527. Epub 2019 Apr 24.

7.

ALS longitudinal studies with frequent data collection at home: study design and baseline data.

Rutkove SB, Qi K, Shelton K, Liss J, Berisha V, Shefner JM.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):61-67. doi: 10.1080/21678421.2018.1541095. Epub 2018 Nov 28.

PMID:
30486680
8.

Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R.

Jackson C, De Carvalho M, Genge A, Heiman-Patterson T, Shefner JM, Wei J, Wolff AA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):506-512. doi: 10.1080/21678421.2018.1497658. Epub 2018 Oct 31.

PMID:
30379086
9.

Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system.

Shefner JM, Rutkove SB, Caress JB, Benatar M, David WS, Cartwright MS, Macklin EA, Bohorquez JL.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):555-561. doi: 10.1080/21678421.2018.1510008. Epub 2018 Sep 28.

PMID:
30265154
10.

Effects of Strength Training in Amyotrophic Lateral Sclerosis: How Much Do We Know?

Shefner JM.

Muscle Nerve. 2019 Jan;59(1):6-7. doi: 10.1002/mus.26347. Epub 2018 Nov 28. No abstract available.

PMID:
30230558
11.

Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.

Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W.

Am J Manag Care. 2018 Apr;24(9 Suppl):S175-S186.

12.

Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale).

Smith RA, Macklin EA, Myers KJ, Pattee GL, Goslin KL, Meekins GD, Green JR, Shefner JM, Pioro EP.

Eur J Neurol. 2018 Jul;25(7):907-e66. doi: 10.1111/ene.13638. Epub 2018 Apr 16. Erratum in: Eur J Neurol. 2018 Oct;25(10):1303.

13.

Respiratory measures in amyotrophic lateral sclerosis.

Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):321-330. doi: 10.1080/21678421.2018.1452945. Epub 2018 Mar 23. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):478.

PMID:
29566571
14.

VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.

Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):259-266. doi: 10.1080/21678421.2018.1426770. Epub 2018 Feb 6. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):321.

PMID:
29402141
15.

Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.

Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM.

JAMA Neurol. 2018 Jan 1;75(1):58-64. doi: 10.1001/jamaneurol.2017.3339.

16.

Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance.

Meng L, Bian A, Jordan S, Wolff A, Shefner JM, Andrews J.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):134-142. doi: 10.1080/21678421.2017.1363242. Epub 2017 Sep 11.

PMID:
28891333
17.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group.

Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28.

18.

An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases: Editorial Introduction.

Shefner JM, Sabbagh MN.

Neurotherapeutics. 2017 Jan;14(1):1-3. doi: 10.1007/s13311-016-0502-y. No abstract available.

19.

Strength Testing in Motor Neuron Diseases.

Shefner JM.

Neurotherapeutics. 2017 Jan;14(1):154-160. doi: 10.1007/s13311-016-0472-0. Review.

20.

Quantitative strength testing in ALS clinical trials.

Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, Cudkowicz M.

Neurology. 2016 Aug 9;87(6):617-24. doi: 10.1212/WNL.0000000000002941. Epub 2016 Jul 6.

Supplemental Content

Loading ...
Support Center